Skip to main content

Tabrecta

Generic name: capmatinib (tablets)
Drug class: Multikinase inhibitors

Medically reviewed by Judith Stewart, BPharm. Last updated on Oct 26, 2022.

What is Tabrecta?

Tabrecta is a prescription medicine used to treat adults with a kind of lung cancer called non-small cell lung cancer (NSCLC) that:

It is not known if this medicine is safe and effective in children.

Before taking Tabrecta

Before taking Tabrecta, tell your healthcare provider about all of your medical conditions, including if you:

Tell your healthcare provider about all the medicines you take or start taking, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I take Tabrecta?

What to avoid

What are the possible side effects of Tabrecta?

Tabrecta may cause serious side effects, including:

The most common side effects include:

These are not all of the possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800 FDA-1088.

How should I store Tabrecta?

Keepall medicines out of the reach of children and pets.

General information about the safe and effective use of Tabrecta.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use this medicine for a condition for which it was not prescribed. Do not give it to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information that is written for health professionals.

What are the ingredients in Tabrecta?

Active ingredient: capmatinib
Inactive ingredients: Tablet core: colloidal silicon dioxide; crospovidone; magnesium stearate; mannitol; microcrystalline cellulose; povidone; and sodium lauryl sulfate.
Tablet coating (150 mg): ferric oxide, red; ferric oxide, yellow; ferrosoferric oxide; hypromellose; polyethylene glycol (PEG) 4000; talc; and titanium dioxide.
Tablet coating (200 mg): ferric oxide, yellow; hypromellose; polyethylene glycol (PEG) 4000; talc; and titanium dioxide.

Popular FAQ

Tabrecta starts working immediately to slow your cancer growth but if you are someone who responds to Tabrecta, it may take a few weeks before your tumors become noticeably smaller or stop growing. 68% of people taking Tabrecta as their first treatment achieved a response.

In clinical studies, the overall response rate (ORR) for Tebrecta in 60 participants who had never received any treatment for non-small cell lung cancer (NSCLC) was 68%, with half of patients having a duration of response lasting 16.6 months. Continue reading

No, Tabrecta is not a cure for lung cancer, but in studies some people saw their tumors shrink or disappear for more than a year. There currently is no cure for lung cancer, but you may be eligible for treatments that could extend your life. Continue reading

Tabrecta (capmatinib) is a targeted chemotherapy drug. It differs from traditional chemotherapy drugs which attack all dividing cells, damaging healthy cells as well as cancerous ones.

Tabrecta targets non-small cell lung cancer (NSCLC) cells with a mutant MET gene lacking exon 14, which is a mutation associated with increased cancer cell growth. Continue reading

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.